Filing search / Tempest Therapeutics, Inc. / "Responsibility" / Page 7

8-K

EX-1.1

924m4ewg1ai7

8 Jan 15

Entry into a Material Definitive Agreement

12:00am

424B5

j3vjft

8 Jan 15

Prospectus supplement for primary offering

12:00am

424B5

4xg7g

6 Jan 15

Prospectus supplement for primary offering

12:00am

8-K

EX-99.1

qrco8c4

11 Dec 14

OvaScience Strengthens Management Team to Support Expanding

12:00am

8-K

EX-10.1

ssnomwpy9wne6eowidhy

18 Sep 14

OvaScience Appoints Jeffrey Young to Chief Financial Officer

12:00am

8-K

EX-1.1

gn5o8lx

6 Mar 14

Entry into a Material Definitive Agreement

12:00am

424B2

bhdz0uu

5 Mar 14

Prospectus for primary offering

12:00am

424B5

m7nvhj8

3 Mar 14

Prospectus supplement for primary offering

12:00am

424B3

dud0ff4bw2a

30 Jul 13

Prospectus supplement

12:00am

424B3

96njw4 3n3ow9bxi

30 Jul 13

Prospectus supplement

12:00am

424B3

tbi5kfdzci9

13 Jun 13

Prospectus supplement

12:00am

424B3

d2577z6 frq8x5hs6xr

13 Jun 13

Prospectus supplement

12:00am

8-K

h9bkzegyfruoggb70u

13 Jun 13

OvaScience Appoints Mary Fisher to Company’s Board of Directors

12:00am

10-K

EX-10.25

qz8uvklv2gcmdepe cts

25 Feb 13

Annual report

12:00am